SCHEMBL2038340

SCHEMBL2038340

CC(Nc1ccnc(-c2cnc3ccc(F)cn23)n1)c1ccc(F)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 0.55
JAK3 P52333 8/20 0.55
JAK1 P23458 4/20 0.55
NTRK1 P04629 7/20 0.40
ALK Q9UM73 4/20 0.40
EIF2AK4 Q9P2K8 4/20 0.38
ABL1 P00519 1/20 0.38
FGR P09769 1/20 0.38
FGFR1 P11362 1/20 0.38
SRC P12931 1/20 0.38
PHKG2 P15735 1/20 0.38
FLT4 P35916 1/20 0.38
FLT3 P36888 1/20 0.38
SIK1 P57059 1/20 0.38
MAP3K9 P80192 1/20 0.38
PTK2 Q05397 1/20 0.38
BTK Q06187 1/20 0.38
ITK Q08881 1/20 0.38
MAPK14 Q16539 1/20 0.38
TSSK2 Q96PF2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2038337 1.00 JAK2 (0.55) JAK2JAK3JAK1NTRK1ALK
SCHEMBL1993891 0.85 JAK2 (0.54) JAK2JAK3JAK1MAPK14
SCHEMBL2035361 0.82 JAK3 (0.54) JAK2JAK3JAK1NTRK1ALK
SCHEMBL2035364 0.82 JAK3 (0.54) JAK2JAK3JAK1NTRK1ALK
SCHEMBL1693860 0.81 JAK3 (0.53) JAK2JAK3JAK1NTRK1FLT3
SCHEMBL16494538 0.81 JAK3 (0.53) JAK2JAK3JAK1NTRK1FLT3
SCHEMBL12067767 0.81 JAK3 (0.53) JAK2JAK3JAK1NTRK1FLT3
SCHEMBL16824738 0.78 JAK3 (0.48) JAK2JAK3JAK1NTRK1ALK
SCHEMBL16824736 0.78 JAK3 (0.48) JAK2JAK3JAK1NTRK1ALK
SCHEMBL2033691 0.78 JAK3 (0.52) JAK2JAK3JAK1NTRK1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US claimed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP claimed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO claimed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 JAK2 2/4885JAK3 3/4885JAK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.